Blog Series: Patient Stratification 

Part 2: Why Is It Important For Study Success? 

Why Stratification Matters

The primary purpose of stratification is to protect the validity and interpretability of your trial.

Stratification protects trial integrity by:

• Reducing baseline imbalance risk
• Improving precision (by reducing variance)
• Enabling pre-specified subgroup analysis
• Strengthening the interpretability of results
• Supporting regulatory confidence

Stratification doesn’t create signal—it prevents you from losing it.

When Should You Stratify?

Stratification is most valuable when certain variables are known—or suspected—to influence outcomes, such as:

• Biomarker status
• Disease severity
• Prior treatment exposure
• Geographic variation

The key is prospective identification. Post hoc subgrouping cannot recover what was not balanced or planned for at the outset.

How Stratification Improves Trial Success

Stratification reduces avoidable noise and ensures fair comparisons.

In practice, it:

• Balances key predictive factors across treatment arms
• Improves the precision of treatment-effect estimates
• Enables credible subgroup insights
• Prevents misleading or unstable results

In hybrid designs, it enables evaluation of both high-response subgroups and the full population—without sacrificing interpretability.

Stratification allows sponsors to:

• Demonstrate efficacy where signal is strongest
• Maintain learnings about the broader population

When properly executed, stratification strengthens:

• Scientific credibility
• Regulatory confidence
• The probability of recognizing true treatment effects

How Stratification Aligns with FDA Guidance

Stratification supports a core regulatory challenge: interpretability vs. generalizability.

FDA guidance on enrichment strategies allows sponsors to focus primary analyses on subgroups more likely to respond (e.g., biomarker-positive) while still learning about the broader population. Regulators expect clarity on what is learned about the enriched population and the non-enriched population. 

Stratification makes this approach defensible. By stratifying on key prognostic or predictive factors, sponsors can:

• Ensure balanced representation across treatment arms
• Reduce the risk that subgroup effects are driven by baseline imbalances
• Support interpretable and regulatory-grade subgroup analyses

FDA Guidance on covariate adjustment further reinforces that pre-specified factors can improve precision, and proper handling of these variables strengthens statistical efficiency.

Critically, both guidance documents emphasize:

• Prespecification of stratification factors
• Control of Type I error when evaluating multiple populations
• Clear interpretation of subgroup findings

Stratification acts as the bridge between identifying where a drug works best and ensuring those findings are scientifically and regulatorily defensible.

Guidance Resources:
FDA Enrichment Strategies for Clinical Trials (2019)

FDA Covariate Adjustment in Randomized Trials (2023)

 Common Pitfalls in Stratification

• Over-stratifying (too many factors)
• Using non-prognostic variables
• Post hoc subgrouping
• Misinterpreting subgroup results

What Makes NetraAI’s Patient Stratification Different?

Traditional stratification relies on a small number of preselected variables, often based on prior knowledge or clinical intuition. While necessary, this approach can miss complex, multi-factor interactions that drive treatment response—especially in small, heterogeneous datasets.

NetraAI takes a data-driven approach, identifying latent subpopulations across multi-dimensional data, instead of relying solely on predefined factors; —especially in small datasets.

This enables:

• More precise identification of high-response groups
• Detection of non-obvious interactions  across clinical, molecular, and demographic variables
• Data-driven stratification that complements—not replaces—clinical expertise
• Improved alignment between trial design and underlying biology

The result is a more refined understanding of:

• Who benefits most
• How to design enrichment strategies
• How to reduce trial risk early

As trials become smaller and more complex, success depends less on enrolling more patients—and more on understanding the patients you already have.

Patient stratification is foundational to that understanding. Stratification ensures that variability informs your study, rather than obscures it.